为什么意大利医疗技术并购看重注册和渠道？
意大利医疗器械、诊断、耗材和医疗服务企业可为中国买方提供欧洲产品和渠道。但医疗技术企业的真实价值取决于注册、质量体系和商业化能力。
买方应区分自有产品收入、经销收入、服务收入和一次性项目收入。
估值重点
估值应关注产品注册、渠道合同、毛利率、临床证据、质量体系、研发管线、库存和售后责任。
尽职调查重点
尽调应覆盖注册文件、质量体系、IP归属、渠道合同、产品责任、召回记录、库存和核心人员。
Lyndon如何协助
Lyndon可协助中国买方、意大利医疗技术企业和顾问准备估值、资料室、监管清单和交易执行。
About the Author
Daniel Bae
Co-founder & CEO, Lyndon Advisory
Daniel is an investment banker with 15+ years of experience in M&A, having advised on deals worth over US$30 billion. His career spans Citi, Moelis, Nomura, and ANZ across London, Hong Kong, and Sydney. He holds a combined Commerce/Law degree from the University of New South Wales. Daniel founded Lyndon Advisory to solve the pain points in M&A, enabling bankers to focus on what matters most — delivering trusted advice to clients.
About Lyndon Advisory
Lyndon Advisory is an M&A advisory firm built for Asia Pacific. We help business owners sell their companies and investors make strategic acquisitions with senior-led execution, disciplined process management, and AI-supported buyer intelligence.
Learn about selling your business